Registry analysis reveals high-risk biomarkers in chronic lymphocytic leukemia patients from Latin America, indicating treatment disparities.
Key Points
Median treatment-free survival was 38 months, showing marked variability in outcomes based on factors such as biomarkers and treatment center type.
Analysis of patients with del(17p) exhibited significantly shorter treatment-free survival at 13 months compared to 25 months for others.
Retrospective data were gathered from a large registry across 11 Latin American countries, highlighting clinical manifestations and treatment outcomes.
Expanding access to molecular diagnostics is crucial for improving care and outcomes in chronic lymphocytic leukemia patients in Latin America.
Cite This Study
Arrais-Rodrigues et al. (2025) studied this question.